, Volume 50, Issue 7–8, pp 423–427 | Cite as

Improved HPLC determination of fluoxetine and norfluoxetine in human plasma

  • M. A. Raggi
  • R. Mandrioli
  • G. Casamenti
  • V. Volterra
  • C. Desiderio
  • S. Fanali


An HPLC method with fluorescence detection has been developed for the determination of fluoxetine and its main metabolite norfluoxetine in human plasma. Pretreatment of the biological samples by liquid-liquid extraction was used to improve the sensitivity of a previously published SPE procedure. The method uses 200 μL plasma and recovery is good for both analytes. On a C8 column with a mixture of perchlorate buffer and acetonitrile as mobile phase fluoxetine, norfluoxetine and the internal standard (paroxetine) were eluted in less than 9 min, without interference from the biological matrix. Response for both analytes was linearly dependent on concentration over the range 2.5–500 ng mL−1, and repeatability (RSD%) was <4%. The limit of detection was 1 ng mL−1 for both fluoxetines. Application to plasma samples from depressed patients treated with fluoxetine gave good results. There was no interference from other common CNS drugs. This method seems to be a useful tool for clinical monitoring, because it requires small plasma samples and is highly sensitive and highly selective.

Key Words

Column liquid chromatography Fluoxetine Norfluoxetine Plasma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    J. P. Feighner, W. F. Boyer, Selective Serotonin Re-uptake Inhibitors, John Wiley & Sons, New York, 1991.Google Scholar
  2. [2]
    P. Benfield, R. C. Heel, S. P. Lewis, Drugs32, 481 (1986).Google Scholar
  3. [3]
    D. Wong, F. Bymaster, E. Engleman, Life Sci.57, 411 (1995).CrossRefGoogle Scholar
  4. [4]
    L. Lemberger, R. F. Bergstrom, R. F. Wolen, J. Clin. Psychol.46, 14 (1985).Google Scholar
  5. [5]
    B. Saletu, J Grunberger, J. Clin. Psychol.46, 45 (1985).Google Scholar
  6. [6]
    J. E. F. Reynolds (Editor), Martindale The Extra Pharmacopoeia, 31st edn, Royal Pharmaceutical Society, London, 1996, p. 312.Google Scholar
  7. [7]
    J. F. Wernicke, J. Clin. Psychol.46, 59, (1985).Google Scholar
  8. [8]
    D. S. Risley, R. J. Bopp, in S. Florey (Editor), Analytical Profiles of Drug Substances, Vol. 19, Academic Press, New York, 1990, p. 215.Google Scholar
  9. [9]
    D. A. Ciraulo, R. I. Shader, J. Clin. Psychopharmacol.10, 48 (1990).Google Scholar
  10. [10]
    J. H. Nichols, J. R. Charlson, J. M. Lawson, Clin. Chem.40, 1312 (1994).Google Scholar
  11. [11]
    F. Centorrino, R. J. Baldessarini, J. C. Kando, F. R. Frankenburg, S. A. Volpicelli, J. G. Flood, J. Clin. Psychopharmacol.14, 119 (1994).Google Scholar
  12. [12]
    A. D'Hulst, N. Verbecke, J. Chromatogr. A735, 283 (1996).CrossRefGoogle Scholar
  13. [13]
    D. D. Wirth, B. A. Olsen, D. K. Hallenbeck, M. E. Lake, S. M Gregg, F. M. Perry, Chromatographia46, 511 (1997).Google Scholar
  14. [14]
    P. Thomare, K. Wang, V. Van Der Meersch-Mougeot, B. Diquet, J. Chromatogr.538, 217 (1992).Google Scholar
  15. [15]
    B. D. Potts, C. J Parli, J. Liq. Chromatogr.15, 665 (1992).Google Scholar
  16. [16]
    A. L. Peyton, R. Carpenter, K. Rutowski, Pharm. Res.8, 1528 (1991).CrossRefGoogle Scholar
  17. [17]
    G. Misztal, H. Hopkala, Pharmazie52, 11 (1997).Google Scholar
  18. [18]
    S. H. Y. Wong, S. S. Dellafera, R. Fernandes, H. Kranzler, J. Chromatogr.499, 601 (1990).CrossRefGoogle Scholar
  19. [19]
    R. F. Suckow, M. F. Zhang, T. B. Cooper, Clin. Chem.38, 1756 (1992).Google Scholar
  20. [20]
    S. Joron, H. Robert, Biomed. Chromatogr.8, 158 (1994).CrossRefGoogle Scholar
  21. [21]
    R. N. Gupta, J. Liq. Chromatogr.16, 2751 (1993).Google Scholar
  22. [22]
    R. N. Gupta, M. Steiner, J. Liq. Chromatogr.,13, 3785 (1990).Google Scholar
  23. [23]
    P. J. Orsulak, J. T. Kenney, J. R. Debus, G. Crowley, P. D. Wittman, Clin. Chem.34, 1267, (1988).Google Scholar
  24. [24]
    A. Ramaiya, C. March, H. T. Karnes, J. Pharm. Biomed. Anal.15, 729 (1997).CrossRefGoogle Scholar
  25. [25]
    S. Pichini, R. Pacifici, I. Altieri, M. Pellegrini, P. Zuccaro, J. Liq. Chromatogr.19, 1927 (1996).Google Scholar
  26. [26]
    M. A. Raggi, R. Mandrioli, G. Casamenti, F. Bugamelli, V. Volterra, J. Pharm. Biomed. Anal.18, 193 (1998).CrossRefGoogle Scholar
  27. [27]
    M. C. Gennaro, C. Abrigo, S. Angelino, U. Albert, F. Bogetto, G. Maina, P. Prolo, L. Ravizza, J. Liq. chromatogr.20, 3017 (1997).Google Scholar
  28. [28]
    M. A. Raggi, F. Bugamelli, G. Casamenti, R. Mandrioli, D. De Ronchi, V. Volterra, J. Pharm. Biomed. Anal.18, 699 (1998).CrossRefGoogle Scholar
  29. [29]
    United States Pharmacopeia, XXIII edn, United States Pharmacopeial Convention, Rockville, MD, 1997, p. 1983.Google Scholar
  30. [30]
    P. R. Puopolo, J. G. Flood, Clin. Chem.37, 1304 (1991).Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1999

Authors and Affiliations

  • M. A. Raggi
    • 1
  • R. Mandrioli
    • 1
  • G. Casamenti
    • 1
  • V. Volterra
    • 2
  • C. Desiderio
    • 3
  • S. Fanali
    • 3
  1. 1.Department of Pharmaceutical SciencesUniversity of BolognaBolognaItaly
  2. 2.Psychiatric ClinicUniversity of BolognaBolognaItaly
  3. 3.CNRInstitute of ChromatographyRomeItaly

Personalised recommendations